Australia- and U.S.-based biotechnology company Vaxxas, which is seeking to commercialize a needle-free vaccination technology, has added Dan Devine as chief business officer and general counsel.

Devine started his career at the Wall Street law firm Dewey Ballantine before spending more than two decades in the biopharmaceutical industry, including a stint at Pfizer, where he headed an international business development group. He also founded, led and took public Patrys, a Melbourne-based developer of anti-cancer antibodies.